source
- FDA pushes back PDUFA date for Capricor's Duchenne therapy to review new dataThe U.S. Food and Drug Administration announced it has extended the PDUFA target date for Capricor Therapeutics' investigational Duchenne muscular dystrophy treatment. The agency said the extensio…
- Bausch + Lomb to launch Phase 3 trial of dry‑eye drop after Phase 2 missBausch + Lomb announced plans to move its dual‑action dry‑eye drop into a Phase 3 study. The decision follows a Phase 2 trial that did not meet its primary endpoint. CEO Brent Saunders said the r…